SC
Stempoint Capital Portfolio holdings
AUM
$311M
1-Year Return
15.22%
This Quarter Return
-10.5%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$313M
AUM Growth
-$85.6M
(-21%)
Cap. Flow
-$51.2M
Cap. Flow
% of AUM
-16.34%
Top 10 Holdings %
Top 10 Hldgs %
50.65%
Holding
79
New
24
Increased
12
Reduced
14
Closed
20
Top Buys
| 1 |
Arcellx
ACLX
|
$18M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$13.6M |
| 3 |
Scholar Rock
SRRK
|
$12.9M |
| 4 |
BridgeBio Pharma
BBIO
|
$7.21M |
| 5 |
CG Oncology
CGON
|
$7.1M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$16.2M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$15.7M |
| 3 |
Incyte
INCY
|
$13.4M |
| 4 |
Merus
MRUS
|
$11.3M |
| 5 |
Praxis Precision Medicines
PRAX
|
$10.3M |
Sector Composition
| 1 | Healthcare | 99.51% |
| 2 | Financials | 0.49% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Protara Therapeutics
TARA
$122M
| $5.07M | 1.62% |
1,190,579
+858,185
| +258% | +$3.66M |
|
27
KalVista Pharmaceuticals
KALV
$765M
| $4.46M | 1.42% |
386,837
-605,966
| -61% | -$6.99M |
|
28
Edgewise Therapeutics
EWTX
$1.54B
| $3.97M | 1.26% |
180,255
+47,549
| +36% | +$1.05M |
|
29
Surrozen
SRZN
$107M
| $2.81M | 0.9% |
240,826
-109,747
| -31% | -$1.28M |
|
30
Protagonist Therapeutics
PTGX
$3.71B
| $2.38M | 0.76% |
49,241
-92,473
| -65% | -$4.47M |
|
31
Enliven Therapeutics
ELVN
$1.19B
| $2.37M | 0.76% |
120,430
+23,714
| +25% | +$467K |
|
32
Neurocrine Biosciences
NBIX
$13.9B
| $2.33M | 0.74% |
+21,052
| New | +$2.33M |
|
33
Ascendis Pharma
ASND
$12B
| $2.3M | 0.73% |
+14,732
| New | +$2.3M |
|
|
BBOT
34
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$798M
| $2.27M | 0.72% |
200,900
| – | – |
|
35
Spyre Therapeutics
SYRE
$1.03B
| $2.2M | 0.7% |
+136,139
| New | +$2.2M |
|
36
Amicus Therapeutics
FOLD
$2.47B
| $2.19M | 0.7% |
+268,919
| New | +$2.19M |
|
37
NewAmsterdam Pharma
NAMS
$2.89B
| $2.14M | 0.68% |
+104,585
| New | +$2.14M |
|
38
Rhythm Pharmaceuticals
RYTM
$6.95B
| $1.79M | 0.57% |
33,816
-174,200
| -84% | -$9.23M |
|
39
Arbutus Biopharma
ABUS
$769M
| $1.63M | 0.52% |
+467,882
| New | +$1.63M |
|
|
PCSC
40
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $1.55M | 0.49% |
150,000
| – | – |
|
41
Geron
GERN
$880M
| $1.53M | 0.49% |
+960,307
| New | +$1.53M |
|
42
IDEAYA Biosciences
IDYA
$2.26B
| $1.1M | 0.35% |
+66,999
| New | +$1.1M |
|
43
Zai Lab
ZLAB
$3.34B
| $955K | 0.3% |
+26,421
| New | +$955K |
|
44
Ocular Therapeutix
OCUL
$2.21B
| $913K | 0.29% |
+124,523
| New | +$913K |
|
45
Dyne Therapeutics
DYN
$1.88B
| $883K | 0.28% |
+84,430
| New | +$883K |
|
46
Soleno Therapeutics
SLNO
$3.7B
| $797K | 0.25% |
+11,155
| New | +$797K |
|
47
InflaRx
IFRX
$106M
| $740K | 0.24% |
+725,019
| New | +$740K |
|
48
Solid Biosciences
SLDB
$433M
| $733K | 0.23% |
+198,150
| New | +$733K |
|
49
Wave Life Sciences
WVE
$1.3B
| $726K | 0.23% |
89,833
-631,376
| -88% | -$5.1M |
|
|
MBX
50
MBX Biosciences, Inc. Common Stock
MBX
$434M
| $713K | 0.23% |
+96,615
| New | +$713K |
|